tradmap

PCSA Financials Processa Pharmaceuticals, Inc.

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Revenue & net income
-$27M -$7M $14M $0 2013 2014 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
0% 50% 100% 2013 2014 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Free cash flow (CFO − capex)
-$11M -$6M $0 2013 2014 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $8M $16M 2013 2014 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$11M $3M $18M $0 2013 2014 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 $14M $6M
2024 -$12M -$11M $1M
2023 -$11M -$8M $5M
2022 $0 -$27M $7M
2021 $0 -$11M $16M
2020 -$14M $15M
2019 -$3M $691536
2018 -$4M $2M
2017 -$2M -$2M $3M
2016 -$2M -$2M $1M
2015 -$3M -$873305 $2090
2014 -$5M -$3M $21234
2014 -$8M -$7M $82248
2013 -$3M -$3M $186864
2013 -$6M -$5M $1M

Frequently asked questions

Is PCSA growing its revenue and profit?

See the revenue and net-income charts above for Processa Pharmaceuticals, Inc.'s multi-year trend.

How much debt does PCSA have?

As of FY2025, Processa Pharmaceuticals, Inc. reported — of total debt against $6M of cash.

What is PCSA's profit margin?

In FY2025, gross margin was —, operating margin —, and net margin —.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.